Ozempic (semaglutide) / Novo Nordisk, Abbott - LARVOL DELTA

SEMAGLUTIDE'S INFLUENCE ON BODY COMPOSITION AND OBJECTIVE PARAMETERS IN OBESE PATIENTS WITH TYPE 2 DIABETES (UEGW 2026) - "Alongside semaglutide, other key therapeutic agents include empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor that prevents glucose reabsorption in the kidneys, and metformin [1-4]... Our findings indicate that after 6 months of treatment, both semaglutide and Synjardy demonstrated comparable efficacy in reducing body weight, blood glucose, HbA1c levels, and systolic blood pressure (p < 0.05)... Semaglutide demonstrates high clinical efficacy in managing type 2 diabetes mellitus, providing significant body weight reduction and ensuring superior patient adherence to the treatment regimen."

Clinical • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Estimating the carbon footprint of oral semaglutide (Rybelsus): a comparative analysis of the medicine carbon footprint model and manufacturer life-cycle assessment in pharmaceutical production. (PubMed, BMJ Open) - "For oral semaglutide, MCF generated lower carbon footprint estimates than manufacturer-reported LCA values, particularly at lower doses, where fixed device/excipient and packaging emissions are proportionally larger. MCF offers a rapid, accessible and indicative estimation method when proprietary data are unavailable. Improved transparency and harmonised boundaries would strengthen comparability between pharmaceutical carbon footprint estimation approaches. These findings are specific to the Rybelsus formulation of oral semaglutide and may not be generalisable to other formulations or GLP-1 RAs."

Clinical • Journal • Diabetes • Endocrine Disorders • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Predictors of Peak Body Weight Loss With Semaglutide in the SELECT Trial. (PubMed, Diabetes Care) - "The peak amount of weight loss expected following initiation of semaglutide cannot be predicted based on clinically available baseline characteristics; unmeasured biological, behavioral, or genetic differences are likely responsible for variability in individual response. Women treated with the highest dose of semaglutide experienced the largest %BWL."

Journal • Atherosclerosis • Cardiovascular • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

Comparative Effectiveness of Once-Weekly Semaglutide Versus Sulfonylureas, DPP4 Inhibitors, and Thiazolidinediones in Patients with Type 2 Diabetes and Chronic Kidney Disease. (PubMed, Adv Ther) - "In real-world practice, OW semaglutide has been associated with sustained benefits in glycemic control, eGFR improvement, weight loss, and SBP reduction over selected oral glucose-lowering medications among patients with T2D and CKD who were ineligible for or with suboptimal response to SGLT2i. It has also been associated with a reduced risk of the composite renal outcome in patients meeting the eligibility criteria for the renal outcome analysis."

HEOR • Journal • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Transplantation • Type 2 Diabetes Mellitus

Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial. (PubMed, Eur Heart J) - "Mediation analyses could not fully ascribe the effects of semaglutide on MACE to known risk factors in SELECT with any certainty. Further investigation of potential additional biomarkers and mediators of semaglutide's cardiovascular protective effect are of interest."

Journal • Cardiovascular • Diabetes • Genetic Disorders • Metabolic Disorders • CRP

The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial (clinicaltrials.gov) - P2 | N=64 | Active, not recruiting | Sponsor: Odense University Hospital | Trial primary completion date: Jan 2026 ➔ Jan 2027

Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

FINESSE-CKD: Optimizing Albuminuria Treatment in CKD With Finerenone and Semaglutide (clinicaltrials.gov) - P2 | N=41 | Completed | Sponsor: University Medical Center Groningen

New P2 trial • Chronic Kidney Disease • Nephrology • Renal Disease

Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea (clinicaltrials.gov) - P=N/A | N=600 | Not yet recruiting | Sponsor: Novo Nordisk A/S | Trial completion date: Oct 2026 ➔ Oct 2027 | Trial primary completion date: Oct 2026 ➔ Aug 2027

Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Comparing Cardiovascular Outcomes in New Users of Oral Semaglutide Versus Other Noninsulin Glucose-Lowering Therapies Among Adults with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. (PubMed, Diabetes Ther) - "Consistent with clinical trial evidence, oral semaglutide was associated with a lower risk of cardiovascular outcomes among people with T2D and ASCVD in real-world settings."

Journal • Atherosclerosis • Cardiovascular • Diabetes • Ischemic stroke • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus

Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial. (PubMed, JAMA Cardiol) - P3 | "Benefits of semaglutide on health-related quality of life appeared greater with higher FI. ClinicalTrials.gov Identifier: NCT03574597."

Clinical • Journal • Retrospective data • Cardiovascular • Congestive Heart Failure • Diabetes • Genetic Disorders • Heart Failure • Metabolic Disorders • Myocardial Infarction • Obesity

Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats. (PubMed, Nat Metab) - "Peptide multi-receptor agonists have advanced obesity treatment, yet challenges remain in achieving maximal weight loss and metabolic control, especially in patients with obesity and type 2 diabetes...Daily co-administration produces dose-dependent reductions in body weight and food intake that exceed both equimolar monotherapies and matched-dose comparator combinations incorporating semaglutide or tirzepatide...Plasma proteomic profiling highlights enrichment of bioenergetic processes with the combination therapy, whereas brain transcriptomic profiling identifies convergent central neuronal programmes linked to energy balance regulation. Collectively, our preclinical findings support five-receptor polypharmacology as a strategy for efficaciously lowering body weight and provide guidance for the design of next-generation unimolecular multi-receptor agonists."

Journal • Preclinical • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus • CALCR

Social Media Discussions of Anti-Diabetic Drugs and the Popularity of GLP-1 Therapies: Content Analysis. (PubMed, JMIR Diabetes) - "Semaglutide-containing drugs such as Ozempic and Mounjaro were the most referenced medications, particularly in weight-loss contexts. This surveillance paper illustrates the current state of public health interests around antidiabetic medications associated with weight loss and raises concerns regarding equitable access for patients with diabetes. These findings underscore the need for updated clinical guidance on necessary lifestyle behaviors for antidiabetic medication use and ongoing monitoring of public opinions regarding chronic disease management medications."

Journal • Diabetes • Genetic Disorders • Metabolic Disorders

Major adverse cardiovascular events in adults with type 2 diabetes escalating to semaglutide 2.0 mg vs switching to tirzepatide (EASD 2026) - "During the baseline period, 67.9%, 25.6%, and 21.9% of the patients received metformin, sodium-glucose cotransporter-2 inhibitors (SGLT2is), and basal insulin, respectively... Among adults with T2D receiving SEMA 1.0 mg, switching to TZP was associated with a higher risk of 3-P MACE relative to escalating to SEMA 2.0. Thus, escalating to SEMA 2.0 mg may offer greater cardiovascular benefits than switching to TZP in adults with T2D."

Adverse events • Clinical • Late-breaking abstract • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

SERENA: Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes (clinicaltrials.gov) - P3 | N=252 | Recruiting | Sponsor: Universitaire Ziekenhuizen KU Leuven | Trial completion date: Dec 2029 ➔ May 2030 | Trial primary completion date: Jun 2029 ➔ Mar 2030

Trial completion date • Trial primary completion date • Diabetes • Gestational Diabetes • Metabolic Disorders

Meant Health Expands Telehealth Access to FDA-Approved GLP-1 Prescriptions, Including Ozempic (Yahoo Finance)

Commercial • Type 2 Diabetes Mellitus

Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema (clinicaltrials.gov) - P3 | N=210 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P3 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

3-month real-world weight outcomes among patients with overweight or obesity after switching from injectable semaglutide or tirzepatide to oral semaglutide for weight management: the OCTANE study (EASD 2026) - "Patients switching from injectable semaglutide or tirzepatide to oral semaglutide for weight management experienced statistically significant weight loss in the 3 months following switch. High treatment satisfaction and adherence were also reported. These early findings support oral semaglutide as an effective alternative for weight management among patients experienced with injectable incretin-based therapies."

Clinical • Late-breaking abstract • Real-world • Real-world evidence • Diabetes • Metabolic Disorders • Obesity

REIMAGINEYOUNG: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes (clinicaltrials.gov) - P3 | N=80 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • LEP • LEPR

A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy (clinicaltrials.gov) - P2 | N=142 | Completed | Sponsor: Novo Nordisk A/S | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Diabetic Neuropathy • Metabolic Disorders • Peripheral Neuropathic Pain • Type 2 Diabetes Mellitus

Novo to share real-world and clinical data including Wegovy pill, and cardiometabolic pipeline progress with next-generation amylin treatments at EASD 2026 (GlobeNewswire) - "New data will highlight the breadth of semaglutide evidence across the cardiometabolic spectrum, including obesity, type 2 diabetes, cardiovascular, kidney and fatty liver disease, and new data on Wegovy pill, Wegovy 7.2 mg and Ozempic 2.0 mg. Real-world evidence from the OCTANE study will provide insights into Wegovy pill use in adults with overweight or obesity, including weight outcomes, treatment switching and patient-reported outcomes. CagriSema and amylin-based pipeline data will provide new insights into appetite regulation, eating behaviour, food noise, body composition and bone health (bone remodelling mechanisms). The data will advance our understanding of the underlying biology of obesity and type 2 diabetes and inform next-generation cardiometabolic innovation."

Clinical data • Cardiovascular • Obesity • Type 2 Diabetes Mellitus

Carbon Emission Impact of Semaglutide in People with Obesity in the UK Using a Disease Modelling Approach. (PubMed, Pharmacoeconomics) - "Semaglutide offers both clinical and environmental benefits in obesity management, supporting the UK's net-zero emissions goals."

Journal • Cardiovascular • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Recent Advances in Glucagon-Like Peptide-1 Receptor and Melanocortin-4 Receptor Agonists for the Treatment of Obesity and Type 2 Diabetes. (PubMed, Horm Metab Res) - "Glucagon-like peptide-1 receptor agonists, such as semaglutide and liraglutide, promote insulin secretion, suppress appetite, and result in effective weight loss and glycemic control...Melanocortin-4 receptor agonists act via the central nervous system to reduce appetite and increase energy expenditure, with setmelanotide showing efficacy in genetic obesity...Glucagon-like peptide-1 receptor and melanocortin-4 receptor agonists, particularly when used as dual or triple agents, represent promising therapeutic innovations for obesity and type 2 diabetes. The development of oral formulations further enhances treatment convenience and adherence, paving the way for improved clinical outcomes."

Journal • Cardiovascular • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Effect of CagriSema on continuous glucose monitoring in people with inadequately controlled type 2 diabetes: REIMAGINE 2 (EASD 2026) - P3 | "Clinical Trial Registration Number: NCT06065540 Background and aims: In REIMAGINE 2, CagriSema, a fixed-dose cagrilintide and semaglutide combination, significantly reduced HbA 1c and body weight (BW) vs its monocomponents in people with type 2 diabetes (T2D) inadequately controlled on metformin ± sodium- glucose cotransporter-2 inhibitor, and overweight/obesity. CagriSema 2.4 mg/2.4 mg and semaglutide 2.4 mg led to clinically relevant improvements in TIR, TITR, PPG curves and TtN. Improvements with CagriSema 2.4 mg/2.4 mg were greatest in people with BL BMI ≥35 kg/m 2; semaglutide 2.4 mg efficacy was consistent regardless of BL BMI. These data support this combination therapy for improved glucose control, especially in people with BMI ≥35 kg/m 2 ."

Late-breaking abstract • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Effect of CagriSema on bone biomarkers in participants with inadequately controlled type 2 diabetes: REIMAGINE 2 (EASD 2026) - P3 | "Treatment with CagriSema, a fixed-dose combination of cagrilintide and semaglutide, leads to substantial weight loss in people with T2D (14.2% weight reduction with CagriSema 2.4 mg/2.4 mg at week 68 in the REIMAGINE 2 trial). CagriSema was associated with changes in CTX-1 and P1NP, that are consistent with reactivation of bone remodelling, in this population with T2D. Even with the substantial weight reduction observed with CagriSema, the stabilisation of CTX-1, coupled with the increase in P1NP from week 20 to 68 provides preliminary reassurance regarding bone changes with CagriSema in T2D."

Biomarker • Late-breaking abstract • Diabetes • Metabolic Disorders • Osteoporosis • Type 2 Diabetes Mellitus

Semaglutide in combination use with SGLT2i reduces cardiovascular events compared to SGLT2i alone use in Chinese patients with type 2 diabetes (EASD 2026) - P | "In a real-world setting, semaglutide in combination use with SGLT2i significantly reduces cardiovascular events compared with SGLT2i alone use in Chinese adults with T2D. These findings support that this combination of semaglutide and SGLT2i confers better cardiovascular protection effects among T2D patients."

Clinical • Late-breaking abstract • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus